China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...
Merus’s Zenocutuzumab Receives Priority Review Status from FDA for Lung and Pancreatic Cancer Indications
Dutch biotechnology company Merus (NASDAQ: MRUS) has announced that the US Food and Drug Administration...
Lei Haichao Takes Over as Party Secretary of China’s National Health Commission
The National Health Commission (NHC) of China has undergone a leadership change, with Lei Haichao...
Betta Pharmaceuticals Files for Market Approval of CDK4/6 Inhibitor BPI-16350 in China
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...
Tonghua Dongbao Pharmaceuticals Commences Phase IIa Trial for Dual-Targeted Gout Drug Candidate
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a China-based pharmaceutical company, has announced that the first patient...
BIO Surveys Members on China-CDMO Dependence Amid BioSecurity Bill Deliberations
The Biotechnology Innovation Organization (BIO), a prominent US industry trade group, is conducting a survey...
Henlius’ HER2 Dual-Targeted Therapy Gets Green Light for Global Phase III Trial by FDA
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced that it has received approval from...
Jacobio Pharma Applies for Approval of KRAS G12C Inhibitor Gecirasib in China
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced the submission of a New...
China’s CDE Gives Tacit Approval to Keymed Biosciences’ Alzheimer’s Drug CM383 for Clinical Trials
The Center for Drug Evaluation (CDE) has indicated on its website that China-based Keymed Biosciences...
Biocytogen and BioCopy AG Collaborate on TCR-Mimic Antibody Development for Cancer Therapies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced an evaluation...
CDE Seeks Public Comment on Latest Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), China’s regulatory body, is currently seeking public feedback on...
GSK’s Q1 2024 Results Beat Forecasts with 10% YOY Revenue Increase; Upgrades Full-Year Outlook
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the first...
Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion
Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of...
Pfizer Appoints Citigroup’s Andrew Baum as Executive Vice-President for Strategy and Innovation
Pfizer Inc. (NYSE: PFE) has announced the appointment of Andrew Baum, M.D., to serve as...
EyePoint Pharmaceuticals’ Durvayu Fails to Meet Primary Endpoint in NPDR Trial
EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT) has announced that its drug candidate Durvayu (vorolanib intravitreal insert;...
Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability
Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of...
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...
Kelun-Biotech’s RET Inhibitor A400 Advances to Phase II Trial with FDA Approval
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, has announced that its...
Everest Medicines’ Nefecon Secures Market Approval for IgAN Treatment in Hong Kong
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, announced that it has received market approval...
Wondfo Biotech’s WELLlife Test Kit Receives FDA Nod for Home Use in the US
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a leading biotechnology company based in China, has...